Search Results

SC66 50 mg  | 99.60%

TargetMol

SC66 is a AKT inhibitor in HepG2, HA22T/VGH, and PLC/PRF/5 cells (IC50: about 0.75 μg/ml, at 72 h).

More Information Supplier Page

SC66 25 mg  | 99.60%

TargetMol

SC66 is a AKT inhibitor in HepG2, HA22T/VGH, and PLC/PRF/5 cells (IC50: about 0.75 μg/ml, at 72 h).

More Information Supplier Page

SC66 10 mg  | 99.60%

TargetMol

SC66 is a AKT inhibitor in HepG2, HA22T/VGH, and PLC/PRF/5 cells (IC50: about 0.75 μg/ml, at 72 h).

More Information Supplier Page

Regadenoson 25 mg  | 99.57%

TargetMol

Regadenoson is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher […]

More Information Supplier Page

Regadenoson 2 mg  | 99.57%

TargetMol

Regadenoson is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher […]

More Information Supplier Page

Regadenoson 50 mg  | 99.57%

TargetMol

Regadenoson is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher […]

More Information Supplier Page

Regadenoson 5 mg  | 99.57%

TargetMol

Regadenoson is an adenosine derivative and selective A2A adenosine receptor agonist with coronary vasodilating activity. Upon administration, regadenoson selectively binds to and activates the A2A adenosine receptor, which induces coronary vasodilation. This leads to an increase in coronary blood flow and enhances myocardial perfusion. Compared to adenosine, regadenoson has a longer half-life and shows higher […]

More Information Supplier Page